Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Helmy Eltoukhy
Person

Helmy Eltoukhy

Tracked across 1 events · 7 articles · First seen Jun 11, 2026 · Last active Jun 11, 2026

Sentiment
0
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 0
Regulatory
FDA approves Guardant360 CDx for HERNEXEOS
The United States — Food and Drug Administration (FDA) has approved Guardant360 CDx, a liquid biopsy test developed by Guardant Health, as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib tablets). HERNEXEOS is the first…
Impact: Helmy Eltoukhy, chairman and co-CEO of Guardant Health, commented on the significance of the FDA approval for Guardant360 CDx, highlighting its impact on advanced cancer care.
Jun 11, 2026 · 7 articles
NEWSDESK
Track Helmy Eltoukhy live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.